News & Resources

Featured Stories

Siren Biotechnology Reveals SRN-101 as Lead Asset for High-Grade Gliomas with Both Orphan Drug and Rare Pediatric Disease Designations from the FDA Read More

Media Coverage | Posted on 6.4.24

MilliporeSigma Announces Siren Biotechnology as Winner of its North American Advance Biotech Grant

Press Releases | Posted on 5.8.24

Siren Biotechnology and Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cancer

Media Coverage | Posted on 4.27.24

How Viral Gene Therapy will Revolutionize Cancer Treatment

Media Coverage | Posted on 4.3.24

Biopharma’s AI Revolution | The Future of Medicine

Media Coverage | Posted on 3.20.24

Venture Europe Podcast – Tackling cancer with gene therapy

Media Coverage | Posted on 3.1.24

Webinar – Undoing the Dogma: A Changing Ethos in AAV Gene Therapy Manufacturing

Media Coverage | Posted on 2.6.24

Exploring the frontiers of gene therapy and AAVs

Press Releases | Posted on 1.15.24

WhiteLab Genomics and Siren Biotechnology Announce Strategic Partnership to Accelerate AI-Powered Advancements in Gene Therapy

Media Coverage | Posted on 12.4.23

The comparability tales: A phase-appropriate roadmap for CGT drug product development

Media Coverage | Posted on 11.9.23

Webinar – Proactive Strategies for Biotech Success in the 2024 Landscape

1 2 3 4